Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02369497 · ClinicalTrials.gov registry record
Ascension® Humeral Resurfacing Arthroplasty (HRA) Follow-Up Study
A clinical trial, sponsored by Integra LifeSciences Corporation.
- Terminated
- Registry status
- 59
- Enrollment target
NCT02369497: Clinical Trial study, sponsored by Integra LifeSciences Corporation.
NCT02369497 is a clinical trial that was terminated before completion, run by Integra LifeSciences Corporation. The registered enrollment target is 59 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02369497 was terminated before completion, sponsored by Integra LifeSciences Corporation.
- TERMINATED
- Registry status
- 59 participants
- Enrollment target
Study Summary
This is a prospective study on the Ascension HRA device to collect data to assess the safety and effectiveness of the HRA.
Primary Outcome
The American Shoulder and Elbow Score is a functional outcome tool that has been validated for various shoulder conditions
Interventions
- DEVICE HRA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2007-12 |
| Est. Completion | 2014-07 |
Why NCT02369497 stopped before completion
NCT02369497 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 59 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which HRA is the first listed.
NCT02369497 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02369497 about?
NCT02369497 is a clinical study titled "Ascension® Humeral Resurfacing Arthroplasty (HRA) Follow-Up Study". This is a prospective study on the Ascension HRA device to collect data to assess the safety and effectiveness of the HRA.
What is the current status of trial NCT02369497?
This trial is currently terminated. The enrollment target is 59 participants. The study started on 2007-12. Estimated completion is 2014-07.
What interventions are being tested in trial NCT02369497?
The interventions under investigation include: HRA (DEVICE).
Who is sponsoring clinical trial NCT02369497?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia